The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by JMP Securities on February 7, 2025. The analyst firm set a price target for $58.00 expecting PTGX to rise to within 12 months (a possible 49.68% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by JMP Securities, and Protagonist Therapeutics reiterated their market outperform rating.

There is no last upgrade for Protagonist Therapeutics

There is no last downgrade for Protagonist Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on February 7, 2025 so you should expect the next rating to be made available sometime around February 7, 2026.

While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a reiterated with a price target of $58.00 to $58.00. The current price Protagonist Therapeutics (PTGX) is trading at is $38.75, which is out of the analyst’s predicted range.